'Telehealth Firms Urge FDA to Legalize Peptides, With Guardrails' - Bloomberg

UBS Maintains Buy on CVS Health, Lowers Price Target to $118

Bill Ackman Backs Mark Cuban's Drug Pricing Model: These Healthcare Stocks Could Win—Or Lose

Bill Ackman backed Mark Cuban's drug pricing model. Here's which healthcare stocks could benefit—and which face pressure.

FDA Says It Has Received 990 Adverse Event Reports Tied To Compounded Semaglutide And More Than 730 Tied To Compounded Tirzepatide; Establishes Import Alert For Compounded GLP-1 Active Pharmaceutical Ingredients

Oil Surges, Treasury Yields Climb a Fifth Day, Software Retreats: Stock Market Today

The 10-year Treasury yield hit a 19-month high and crude jumped above $88 as traders lifted Fed rate-hike odds to 68%, cracking high-multiple software stocks.

Barclays Maintains Equal-Weight on Doximity, Raises Price Target to $27

Barclays analyst Glen Santangelo maintains Doximity (NYSE:DOCS) with a Equal-Weight and raises the price target from $20 to $27.

What Investors Should Know of This Doximity Officer's Latest Insider Transaction

Doximity's Chief Accounting Officer Siddharth Sitaram sold 5,652 shares worth $140,400 in mid-August. The transaction was driven by routine tax obligations from option exercises and restricted stock unit vesting rather than a loss of confidence in the company. Sitaram retains significant equity holdings of 93,122 shares. The sale reflects standard tax-driven liquidity management common among executives.